Source: CureToday articles
Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC.
Recent Content
- (no title)
- (no title)
- (no title)
- Prostate cancer tool may cut risk for women in radiation therapy
- Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma
- (no title)
- (no title)
- (no title)
- FDA OKs multiple myeloma combo for all newly diagnosed patients
- Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review